Skip to content

Eli Lilly and Co

US · LLY #11 by market cap Listed 1970 Quant Rating B 82
1,149.36 -10.24 -0.88%
Collector offline (last heartbeat: 19189s ago) · 2026-09-04 20:02
Pre-market 1,150.65 -0.77%
After-hours 1,146.65 -0.24%
Overnight 1,158.00 -0.14%
Market cap
1.08T
P/B
31.94
EPS
22.95

Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 14 in the most recent period (2026/Q3).
  • Total institutional ownership (as a % of shares) was little changed.

Institutional ownership

Held by institutions
79.21% -0.06pp
Institutions
5,290 -14
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund61.57%
Public Company9.48%
Private Company3.03%
Government Pension Fund1.87%
Sovereign Wealth Fund1.37%
Hedge Fund0.93%
Family Office/Trust0.40%
Corporate Pension Plan0.20%
Individual/Insider0.17%
Other20.98%

Top holders

HolderStake
BlackRock7.58%
Vanguard Capital Management, LLC6.52%
The PNC Financial Services Group, Inc.5.74%
Capital Research4.82%
State Street Global Advisors4.06%
Other71.28%

Insiders

31 filings tracked · 5 buys · 5 sells

NameRoleStake
David Ricks Chairperson & CEO 0.09%
Daniel Skovronsky EVP, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology 0.03%
Anne White EVP & President of Lilly Neuroscience 0.01%
Patrik Jonsson EVP, Chief Customer Officer, President of Lilly Diabetes & Obesity and President Lilly USA 0.01%
Anat Hakim General Counsel 0.01%
Edgardo Hernandez EVP & President of Manufacturing Operations 0.01%
Anat Ashkenazi Chief Financial Officer 0.00%
Jacob Van Naarden EVP, CEO of Loxo Oncology & President of Lilly Oncology 0.00%
Ilya Yuffa EVP & President of Lilly International 0.00%
Diogo Rau EVP & Chief Information and Digital Officer 0.00%

Quote time 2026-09-04 20:02:22

For reference only, not investment advice.